scholarly journals KANK1 inhibits cell growth by inducing apoptosis through regulating CXXC5 in human malignant peripheral nerve sheath tumors

2017 ◽  
Vol 7 (1) ◽  
Author(s):  
Zhibin Cui ◽  
Yingjia Shen ◽  
Kenny H. Chen ◽  
Suresh K. Mittal ◽  
Jer-Yen Yang ◽  
...  

Abstract Malignant peripheral nerve sheath tumors (MPNSTs) are a type of rare sarcomas with a poor prognosis due to its highly invasive nature and limited treatment options. Currently there is no targeted-cancer therapy for this type of malignancy. Thus, it is important to identify more cancer driver genes that may serve as targets of cancer therapy. Through comparative oncogenomics, we have found that KANK1 was a candidate tumor suppressor gene (TSG) for human MPNSTs. Although KANK1 is known as a cytoskeleton regulator, its tumorigenic function in MPNSTs remains largely unknown. In this study, we report that restoration of KANK1 in human MPNST cells inhibits cell growth both in human cell culture and xenograft mice by increasing apoptosis. Consistently, knockdown of KANK1 in neurofibroma cells promoted cell growth. Using RNA-seq analysis, we identified CXXC5 and other apoptosis-related genes, and demonstrated that CXXC5 is regulated by KANK1. Knockdown of CXXC5 was found to diminish KANK1-induced apoptosis in MPNST cells. Thus, KANK1 inhibits MPNST cell growth though CXXC5 mediated apoptosis. Our results suggest that KANK1 may function as a tumor suppressor in human MPNSTs, and thus it may be useful for targeted therapy.

2003 ◽  
Vol 143 (2) ◽  
pp. 120-124 ◽  
Author(s):  
Nadine Van Roy ◽  
Mireille Van Gele ◽  
Jo Vandesompele ◽  
Ludwine Messiaen ◽  
Simon Van Belle ◽  
...  

Oncotarget ◽  
2018 ◽  
Vol 9 (34) ◽  
pp. 23494-23504
Author(s):  
Rashmi Kumari ◽  
Martin R. Silic ◽  
Yava L. Jones-Hall ◽  
Alexandra Nin-Velez ◽  
Jer-Yen Yang ◽  
...  

2021 ◽  
Vol 23 (Supplement_6) ◽  
pp. vi115-vi115
Author(s):  
Yoon Jae Choi ◽  
Mari Perez-Rosendahl

Abstract Hybrid nerve sheath tumors are new disease entity incorporated in WHO classification of tumors of the central nervous system 2016 version that includes benign peripheral nerve sheath tumors with combined features of more than one conventional type. Ronellenfitsch et al recently reported one case with ERBB2 D769Y mutation with good clinical response to lapatinib in 2020. We report two cases with imaging findings of multiple peripheral nerve sheath tumors with pathology proven hybrid nerve sheath tumors with ERBB2 mutations. Patient 1 has neurofibroma/schwannoma hybrid nerve sheath tumor with ERBB2 D769Y mutation and patient 2 has plexiform neurofibroma/schwannoma hybrid nerve sheath tumor with ERBB2 V777L mutation. Both of our patients have similar clinical features with adult-onset multiple peripheral nerve sheath tumors without other systemic features of neurofibromatosis type1 or vestibular schwannomas or family history. Hybrid nerve sheath tumors are newly recognized disease and more than half of the cases have multiple peripheral nerve sheath tumors, suggestive of tumor syndrome. Patients with multiple peripheral nerve sheath tumors without systemic features of neurofibromatosis type1 or vestibular schwannomas should be screened for genetic/molecular tests including ERBB2 mutation that might provide treatment options for these patients.


Author(s):  
Inga-Marie Schaefer ◽  
Armelle Dufresne ◽  
Nacef Bahri ◽  
Marije A. J. de Rooij ◽  
Stacy M. Yanofsky ◽  
...  

BMC Cancer ◽  
2013 ◽  
Vol 13 (1) ◽  
Author(s):  
Jun Ohishi ◽  
Mikiko Aoki ◽  
Kazuki Nabeshima ◽  
Junji Suzumiya ◽  
Tamotsu Takeuchi ◽  
...  

2017 ◽  
Vol 7 (1) ◽  
Author(s):  
Zhibin Cui ◽  
Yingjia Shen ◽  
Kenny H. Chen ◽  
Suresh K. Mittal ◽  
Jer-Yen Yang ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document